![Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997]()
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997Lucas, David M.; Ruppert, Amy S.; Lozanski, Gerard; Dewald, Gordon W.; Lozanski, Arletta; Claus, Rainer; Plass, Christoph; Flinn, Ian W.; Neuberg, Donna S.; Paietta, Elisabeth M.; Bennett, John M.; Jelinek, Diane F.; Gribben, John G.; Hussein, Mohamad A.; Appelbaum, Frederick R.; Larson, Richard A.; Moore, Dennis F.; Tallman, Martin S.; Byrd, John C.; Grever, Michael R. · Leukemia & Lymphoma · 2015